Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Amgen
(NQ:
AMGN
)
309.89
+3.90 (+1.27%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amgen
< Previous
1
2
3
4
5
6
7
8
9
...
41
42
Next >
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
June 20, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Where Will Amgen Be in 5 Years?
June 20, 2024
Can Amgen be a market-beating stock?
Via
The Motley Fool
Check Out What Whales Are Doing With AMGN
June 18, 2024
Via
Benzinga
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
June 17, 2024
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities.
Via
InvestorPlace
Expert Ratings For Amgen
June 14, 2024
Via
Benzinga
Decoding Amgen's Options Activity: What's the Big Picture?
June 12, 2024
Via
Benzinga
Market Whales and Their Recent Bets on AMGN Options
June 06, 2024
Via
Benzinga
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
June 20, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines
June 17, 2024
Biotechnology firm Moderna Inc. (NASDAQ: MRNA) made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA
Via
MarketBeat
Exposures
COVID-19
Here's How Much You Would Have Made Owning Amgen Stock In The Last 20 Years
May 31, 2024
Via
Benzinga
Where Will Amgen Be in 3 Years?
May 29, 2024
The Amgen of 2027 could be much be larger than some investors expect.
Via
The Motley Fool
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $5,700 Today
May 21, 2024
Via
Benzinga
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
June 13, 2024
The companies are closing in on the finish line for two new COPD treatments.
Via
Investor's Business Daily
3 Stocks to Buy as Ozempic Surges in Popularity
June 13, 2024
Ozempic has surged in popularity in recent years, but the best may be to come as innovators look to launch new drugs to meet hot demand.
Via
InvestorPlace
Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club
June 12, 2024
Enthusiasm is growing for a looming approval in COPD treatment.
Via
Investor's Business Daily
Skye Bioscience Pivots To Obesity After Glaucoma Flop; Shares Plummet
June 10, 2024
The company is focusing on obesity treatment after its glaucoma drug failed.
Via
Investor's Business Daily
Is Geron Stock a Buy Following Its First New Drug Approval?
June 08, 2024
Find out if the high-flying biotech stock can keep on climbing higher.
Via
The Motley Fool
Amgen Seeks Expanded US Approval For Autoimmune Disease Drug Acquired Via $28B Horizon Deal
June 05, 2024
Amgen announced Phase 3 trial results for Uplizna for IgG4-related disease, achieving an 87% reduction in flare risk. All key secondary endpoints were met with no new safety signals.
Via
Benzinga
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
June 03, 2024
There's probably a big enough pie here for everyone to get a slice.
Via
The Motley Fool
Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug
May 29, 2024
The FDA has approved Amgen's Bkemv as the first interchangeable biosimilar to AstraZeneca's Soliris for treating rare diseases.
Via
Benzinga
Exposures
Product Safety
OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF
May 28, 2024
As weight loss drugs are gaining popularity Roundhill GLP 1 And Weight Loss ETF (OZEM) has launched as anew way to invest in them.
Via
InvestorPlace
Topics
ETFs
Amgen's Catching Up to Novo Nordisk and Eli Lilly. Should You Buy It?
May 26, 2024
The gold rush for obesity medications just got a bit more intense.
Via
The Motley Fool
What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?
May 24, 2024
Verastem Oncology reports promising initial results from the RAMP 205 trial with an 83% ORR for avutometinib and defactinib in metastatic pancreatic cancer. FDA submission for recurrent KRAS mutant...
Via
Benzinga
Exposures
Product Safety
Stocks to Buy: 7 Undeniable Dow Darlings to Pile Into Now
May 24, 2024
Most Dow stocks are strong investments but these 7 stand out at the moment as the macroenvironment trends positive again.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
May 21, 2024
Roundhill CEO Dave Mazza says investors "can't just buy a basket of big pharma names or a broad-based biotech ETF and call it a day."
Via
Benzinga
Topics
ETFs
7 Reliable Blue-Chip Stocks That Cannot Miss
May 21, 2024
These reliable blue-chip stocks to own are the closest thing to slam dunk investments that exist. Discover why you should buy them now.
Via
InvestorPlace
Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
May 20, 2024
Amgen and AstraZeneca reveal Phase 2a results for Tezspire in severe COPD, showing a 17% reduction in exacerbations, with notable improvements in lung function and quality of life for patients with...
Via
Benzinga
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
May 20, 2024
Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions.
Via
InvestorPlace
Dow Jones Industrial Average Closes Above 40,000 In Quiet Friday Climb
May 19, 2024
The Dow Jones Industrial Average closed above the 40,000.00 major handle for the first time ever after markets wound down a hectic trading week that saw rate cut hopes return to the forefront after US...
Via
Talk Markets
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Is Amgen a Threat to Eli Lilly in This Billion-Dollar Market?
May 19, 2024
Eli Lilly's biggest growth drivers today are its weight loss drugs.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
41
42
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.